BlackRock
ADCT icon

BlackRock’s ADC Therapeutics ADCT Stock Holding History

BlackRock’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.51M Buy
7,020,093
+769,346
+12% +$2.24M ﹤0.01% 3797
2026
Q1 		$23.4M Buy
6,250,747
+823,438
+15% +$3.25M ﹤0.01% 2976
2025
Q4 		$19.2M Buy
5,427,309
+915,610
+20% +$3.72M ﹤0.01% 3130
2025
Q3 		$18M Sell
4,511,699
-9,644
-0.2% -$30.4K ﹤0.01% 3146
2025
Q2 		$12.1M Sell
4,521,343
-392,285
-8% -$825K ﹤0.01% 3312
2025
Q1 		$6.93M Sell
4,913,628
-98,229
-2% -$167K ﹤0.01% 3494
2024
Q4 		$9.97M Buy
5,011,857
+612,723
+14% +$1.6M ﹤0.01% 3431
2024
Q3 		$13.9M Buy
4,399,134
+844,392
+24% +$2.66M ﹤0.01% 3237
2024
Q2 		$11.2M Buy
+3,554,742
New +$14.1M ﹤0.01% 3326
2023
Q4 		– Sell
-529,890
Closed -$475K – 5377
2023
Q3 		$475K Buy
529,890
+61,385
+13% +$81.7K ﹤0.01% 4436
2023
Q2 		$1.01M Sell
468,505
-167,042
-26% -$376K ﹤0.01% 4294
2023
Q1 		$1.24M Buy
635,547
+108,756
+21% +$401K ﹤0.01% 4259
2022
Q4 		$2.02M Buy
526,791
+98,925
+23% +$396K ﹤0.01% 4128
2022
Q3 		$2.06M Sell
427,866
-38,938
-8% -$282K ﹤0.01% 4182
2022
Q2 		$3.71M Buy
466,804
+162,575
+53% +$1.54M ﹤0.01% 3955
2022
Q1 		$4.47M Buy
304,229
+10,372
+4% +$165K ﹤0.01% 4029
2021
Q4 		$5.94M Sell
293,857
-19,784
-6% -$477K ﹤0.01% 3923
2021
Q3 		$8.52M Buy
313,641
+12,903
+4% +$330K ﹤0.01% 3742
2021
Q2 		$7.32M Buy
+300,738
New +$6.98M ﹤0.01% 3761
2021
Q1 		– Sell
-165,021
Closed -$5.28M – 5269
2020
Q4 		$5.28M Hold
165,021
– – ﹤0.01% 3686
2020
Q3 		$5.44M Buy
165,021
+521
+0.3% +$22.6K ﹤0.01% 3536
2020
Q2 		$7.7M Buy
+164,500
New +$6.24M ﹤0.01% 3335

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock's ADCT Position: Q2 2026 in Review

BlackRock increased its ADC Therapeutics (ADCT) stake by 12% in Q2 2026, buying an estimated $2.24M and bringing the position to 7,020,093 shares worth $7.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3797.

BlackRock first reported a position in ADCT in Q2 2020 and has held it in 22 quarters since. The position peaked at $23.4M in Q1 2026. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • BlackRock held 7,020,093 shares of ADC Therapeutics worth $7.51M as of Q2 2026.
  • BlackRock bought 769,346 ADC Therapeutics shares in Q2 2026, an estimated $2.24M.
  • ADC Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3797 holding.
  • BlackRock first reported a position in ADC Therapeutics in Q2 2020 and has held it in 22 quarters since.
  • BlackRock's ADC Therapeutics position peaked at $23.4M in Q1 2026.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.